Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
June 10, 2017 13:00 ET
|
Zafgen, Inc.
-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical...
Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions
June 05, 2017 08:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use...
PTS Diagnostics will Present at the American Diabetes Association’s (ADA) 76th Scientific Sessions
June 09, 2016 06:00 ET
|
PTS Diagnostics
INDIANAPOLIS, June 09, 2016 (GLOBE NEWSWIRE) -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care blood testing devices including the CardioChek® and A1CNow® systems, will exhibit and...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
August 16, 2015 20:28 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
Type 2 Diabetes Trial Results Published In Diabetes Care
July 22, 2015 19:17 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
June 08, 2015 21:12 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
May 18, 2015 05:39 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment...
Type 2 Diabetes Trial Results Presented by Study Investigators at American Diabetes Association Annual Meeting
June 18, 2014 23:19 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 18, 2014 (GLOBE NEWSWIRE) -- Results from the Phase 2 trial of Mesoblast's proprietary adult stem cells in type 2 diabetes patients have been presented by Jay...
Keller Rohrback L.L.P. Investigates Telemarketer InfoCision Management Corporation Regarding Allegedly False and Misleading Donation Solicitations
October 19, 2012 18:51 ET
|
Keller Rohrback L.L.P.
SEATTLE, Oct. 19, 2012 (GLOBE NEWSWIRE) -- Attorney Advertising Material. Keller Rohrback announces its investigation of InfoCision Management Corporation ("InfoCision" or the "Company"), an...
Independence Blue Cross Gears Up to Step Out
May 15, 2012 14:30 ET
|
Independence Blue Cross
PHILADELPHIA, May 15, 2012 (GLOBE NEWSWIRE) -- In April, Independence Blue Cross (IBC) marked the company's fifth-year presenting sponsorship of Step Out: Walk to Stop Diabetes, the American Diabetes...